Login to Your Account



Mavupharma raises $20M series A for STING therapies

By Michael Fitzhugh
Staff Writer

Thursday, December 21, 2017

Mavupharma Inc., a new company developing therapies for cancer and infectious diseases, recently secured a $20 million series A financing led by Frazier Healthcare Partners, joined by Alpine Bioventures.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription